Drug Trial Radar · NCT00717236
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Last checked: Nov 20, 2026Latest source record: Aug 1, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,648
Actual
Start
Jul 2008
Primary completion
Mar 2010
Study completion Mar 2011
Sponsor
- Lead sponsor
- UCB PharmaUCB
- Sponsor type
- Industry
- First posted
- Jul 17, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase IIIb multicenter study to evaluate the safety and efficacy of certolizumab pegol (CZP) administered to patients with moderate-to-severe rheumatoid arthritis.
Conditions
- Rheumatoid Arthritis
Interventions
Certolizumab pegol (CZP)Drug
400 mg CZP given as two 200 mg subcutaneous (sc) injections at Weeks 0, 2, and 4, followed by 200 mg CZP given as 1 sc injection on Weeks 6, 8, and 10. At Week 12 subjects enter the open label phase and receive 200 mg of CZP every other week for a minimum 16 additional weeks until CZP is commercially available.
PlaceboOther
Placebo (0.9% saline) given as 2 subcutaneous (sc) injections at Weeks 0, 2, and 4, followed by placebo given as 1 sc injection on Weeks 6, 8, and 10. At Week 12 subjects enter the open label phase and receive 200 mg of CZP every other week for a minimum 16 additional weeks until CZP is commercially available.
Primary outcomes
What the sponsor says the trial is designed to measure.
- American College of Rheumatology 20% (ACR20) Response at Week 12Time frame: Baseline, Week 12
Locations
181 sites in 7 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Montgomery, Alabama
Site not named
Phoenix, Arizona
Site not named
Tucson, Arizona
Site not named
Hot Springs, Arkansas
Site not named
Little Rock, Arkansas
Site not named
Fullerton, California
Site not named
La Jolla, California
Site not named
Los Angeles, California
Site not named
Palm Desert, California
Site not named
Sacramento, California
Site not named
Santa Barbara, California
Site not named
Santa Maria, California
Site not named
Tustin, California
Site not named
Westlake Village, California
Site not named
Whittier, California
Site not named
Denver, Colorado
Site not named
Danbury, Connecticut
Site not named
Trumbull, Connecticut
Site not named
Lewes, Delaware
Site not named
Newark, Delaware
Site not named
Washington D.C., District of Columbia
Site not named
Boca Raton, Florida
Site not named
Delray Beach, Florida
Site not named
Gainesville, Florida
Site not named
Jacksonville, Florida
Site not named
Orlando, Florida
Site not named
South Miami, Florida
Site not named
Tampa, Florida
Site not named
Tavares, Florida
Site not named
Atlanta, Georgia
Site not named
Coeur d'Alene, Idaho
Site not named
Idaho Falls, Idaho
Site not named
Maywood, Illinois
Site not named
Peoria, Illinois
Site not named
Rock Island, Illinois
Site not named
Springfield, Illinois
Site not named
Evansville, Indiana
Site not named
Indianapolis, Indiana
Site not named
Wichita, Kansas
Showing 40 of 181 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.